Targeting APP and TFRC with a Novel Humanized Nanobody Construct for Alzheimer's Disease
VHH-P841 is an innovative humanized nanobody-based therapeutic construct designed to target both amyloid beta precursor protein (APP) and transferrin receptor (TFRC). Expressed in human embryonic kidney cells, this biospecific molecule features an advanced fusion format, integrating a shark-derived variable domain for TFRC targeting and a humanized antibody fragment for amyloid-beta. VHH-P841 is currently in the Biological Testing stage and holds significant promise for Alzheimer's disease treatment by addressing two pivotal molecular pathways implicated in disease progression. This dual-targeting strategy is positioned to offer advantages in both specificity and therapeutic efficacy.
| Candidate | VHH-P841 |
| Target | amyloid beta precursor protein (APP) transferrin receptor (TFRC) |
| Modality | humanized bispecific VHH |
| Indication | Alzheimer's Disease |
Licensing Opportunity
VHH-P841 is available for out-licensing and strategic collaboration. We invite partners interested in cutting-edge therapeutics for neurodegenerative diseases to contact us regarding research, co-development, or commercialization opportunities.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P841 |
Modality
VHH-P841 is an iodine 125-labeled fusion construct incorporating a single-domain nanobody specific for TFRC, joined by a (G4S)3 linker to a humanized IgG1 antibody fragment targeting amyloid-beta. The Fc region includes L234A, L235A, and G237A mutations to optimize effector function. This modular nanobody-antibody format leverages the small size, high stability, and deep tissue penetration characteristic of nanobodies, while maintaining the pharmacokinetic benefits of IgG1. The design facilitates BBB transcytosis by engaging TFRC, potentially enhancing delivery to the brain and enabling effective targeting of Alzheimer's disease-associated amyloid pathology.
Target
APP and TFRC are strategically important targets for modulating Alzheimer's disease pathology. APP is a membrane protein primarily expressed in neuronal tissues, serving as the precursor to amyloid-beta peptides implicated in plaque formation. Dysregulation of APP processing is central to Alzheimer's disease etiology. TFRC, widely expressed on endothelia and neurons, is vital for iron uptake and transport, but also enables molecular transport across the BBB. Targeting TFRC facilitates enhanced CNS penetration of therapeutic agents. Dual engagement of APP and TFRC by VHH-P841 presents a unique advantage, combining disruption of amyloidogenic cascades with improved delivery into the brain, supporting a comprehensive and innovative therapeutic approach. Integrating APP and TFRC targeting underscores the program’s competitive potential in the evolving landscape of Alzheimer’s disease interventions.
Mechanism of Action
VHH-P841 exerts its therapeutic effect through simultaneous engagement of APP and TFRC. By binding APP, the construct acts as an antiamyloidogenic agent, potentially interfering with amyloid-beta generation and aggregation, thereby addressing one of the core mechanisms of Alzheimer’s disease pathology. Concurrently, targeting TFRC leverages receptor-mediated transcytosis, promoting efficient transport across the blood-brain barrier and enhancing drug distribution within the CNS. The radiolabeling with iodine 125 allows for potential imaging or tracking applications. This versatile platform demonstrates utility not only as a bispecific therapeutic but also as a scaffold for developing advanced antibody-drug conjugates and next-generation multispecific modalities targeting neurodegenerative diseases.
Alzheimer's Disease
Alzheimer’s disease is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. It is primarily characterized by cognitive decline, memory loss, and behavioral disturbances, with hallmark pathological features including amyloid plaques and neurofibrillary tangles. The global burden of Alzheimer's disease is significant, with increasing prevalence due to aging populations. Current treatment approaches primarily include symptomatic management with acetylcholinesterase inhibitors and NMDA receptor modulators, while disease-modifying strategies are still limited and under active investigation. Existing therapies offer only modest improvements and do not halt disease progression. Major unmet needs include effective disease modification, improved CNS drug delivery, and combination strategies targeting multiple pathological pathways. VHH-P841, with its dual targeting of APP and TFRC, is positioned to address these gaps by combining antiamyloidogenic action with enhanced brain penetration, representing a promising advancement for patients and caregivers under the current therapeutic landscape.